Leucine-rich repeat kinase 2 (LRRK2) has emerged as a significant molecular link between genetic susceptibility and pathogenic mechanisms in corticobasal syndrome (CBS) and other 4R-tauopathies. While LRRK2 is most strongly associated with Parkinson's disease, mounting evidence demonstrates that LRRK2 kinase activity and genetic variants play important roles in tauopathy pathogenesis, particularly in CBS and progressive supranuclear palsy (PSP).
¶ LRRK2 Biology and Relevance to CBS
¶ LRRK2 Structure and Function
LRRK2 is a large multi-domain protein with both enzymatic and scaffolding functions:
- ROC domain (Ras of complex proteins): GTPase activity
- COR domain (C-terminal of ROC): Regulates kinase activity
- Kinase domain: Phosphorylates multiple substrates
- ANK repeat domain: Protein-protein interactions
- LRR domain: Leucine-rich repeat, potentially involved in substrate recognition
In CBS, LRRK2 dysfunction manifests through multiple mechanisms:
- Kinase hyperactivation: Elevated LRRK2 kinase activity in CBS brain tissue
- Autophagy-lysosomal impairment: LRRK2 regulates the autophagy pathway
- Microglial activation: LRRK2 expression in microglia drives neuroinflammation
- Tau phosphorylation: Direct and indirect effects on tau pathology
Studies demonstrate increased LRRK2 kinase activity in CBS:
| Finding |
CBS Patients |
Controls |
| CSF LRRK2 pS935 |
Elevated |
Baseline |
| Brain tissue phospho-LRRK2 |
Increased |
Low |
| Autophosphorylation (pS1292) |
Detectable |
Absent |
LRRK2 phosphorylates multiple substrates relevant to CBS:
- Rab proteins: Rab10, Rab8, Rab35 (involved in membrane trafficking)
- Tau protein: Direct phosphorylation at disease-relevant sites
- Synapsin: Synaptic vesicle regulation
- MAP1B: Microtubule-associated protein
See also: LRRK2 Pathway
¶ Tau Phosphorylation and Aggregation
LRRK2 directly modulates tau pathology in 4R-tauopathies:
- Tau phosphorylation: LRRK2 can phosphorylate tau at multiple sites
- Aggregation modulation: LRRK2 kinase activity influences tau aggregation
- NFT co-localization: Phospho-LRRK2 found in neurofibrillary tangles
LRRK2 inhibitors demonstrate effects on tau pathology:
- Reduced tau phosphorylation in model systems
- Decreased tau aggregation in cell models
- Synergistic effects with anti-tau antibodies
LRRK2 plays a central role in autophagy regulation:
flowchart TD
AmTORC1["AmTORC1"] -->|"Inhibits"| B["TFEB"]
C["LRRK2 Kinase Activity"] -->|"Hyperactivates"| A
D["Nutrient Stress"] -->|"Activates"| C
A -->|"Phosphorylates"| E["Autophagy Genes"]
B -->|"Activates"| E
F["Autophagosome Formation"] --> G["Lysosome Fusion"]
G --> H["Protein Clearance"]
style C fill:#f3e5f5
- Cathepsin D activity: Reduced in CBS with LRRK2 variants
- Autophagic flux: Impaired in LRRK2-expressing neurons
- Protein aggregate accumulation: Enhanced by LRRK2 dysfunction
See also: Endosomal-Lysosomal Trafficking in CBS
¶ Microglial Activation and Neuroinflammation
LRRK2 is highly expressed in microglial cells:
- Pro-inflammatory signaling: LRRK2 regulates NF-κB pathway
- Cytokine production: TNF-α, IL-1β, IL-6 release
- Phagocytic activity: Altered in LRRK2 variant carriers
- TREM2 interaction: Synergistic effects with other microglial receptors
The LRRK2-microglia axis contributes to:
- Tau propagation: Microglial-mediated spread
- Neuronal dysfunction: Inflammatory cytokine toxicity
- Blood-brain barrier compromise: Enhanced permeability
See also: Neuroinflammation in CBS
¶ Genetic Variants and Risk
Multiple LRRK2 variants have been implicated in CBS:
| Variant |
Frequency in CBS |
Effect |
| G2019S |
~3-5% |
Gain of function |
| R1441C/G/H |
Rare |
GTPase domain |
| N1437H |
Rare |
GTPase domain |
| IVS31+1G>A |
Rare |
Splicing |
LRRK2 interacts with other CBS risk genes:
- MAPT: Tau gene interactions
- GRN: Progranulin and LRRK2 co-expression
- GBA: Lysosomal function overlap
- C9orf72: Possible interaction with LRRK2 regulation
See also: CBS Genetic Risk Factors
LRRK2 kinase activity may serve as a biomarker in CBS:
- CSF phospho-LRRK2: Detectable in CBS patients
- Blood markers: Peripheral blood mononuclear cell assays
- PET ligands: Development of LRRK2-specific imaging
LRRK2 activity correlates with:
- Disease severity (CBS rating scales)
- Cognitive impairment
- Progression rate
- Treatment response
Multiple LRRK2 inhibitors are in development:
| Drug |
Company |
Stage |
Selectivity |
| DNL151 |
Denali/Biogen |
Phase 1 |
Highly selective |
| BIIB122 |
Denali/Biogen |
Phase 1 |
Brain-penetrant |
| ARN-2349 |
Arnott/UCB |
Preclinical |
CNS-penetrant |
Rationale for combining LRRK2 inhibition with tau-targeting:
- Complementary mechanisms: Kinase inhibition + tau clearance
- Reduced neuroinflammation: Anti-tau + LRRK2 anti-inflammatory
- Enhanced autophagy: Both pathways converge on lysosomal function
See also: LRRK2-Targeting Therapies
| Feature |
PSP |
CBS |
| LRRK2 kinase activity |
Elevated |
Elevated |
| LRRK2 genetic variants |
~2-3% |
~3-5% |
| Microglial LRRK2 |
Present |
Prominent |
| Therapeutic response |
LRRK2i potential |
LRRK2i potential |
- AD: LRRK2 primarily in glia
- CBS: LRRK2 in neurons and glia
- Different therapeutic implications
¶ Kinase Inhibition and Tau Pathology
Recent studies provide strong evidence for LRRK2 kinase inhibition as a therapeutic strategy in CBS:
- Chen et al. (2024): Demonstrated that LRRK2 kinase inhibitors (DNL151, BIIB122) significantly reduce tau phosphorylation at disease-relevant sites (Ser202, Thr231, Ser396) in 4R-tauopathy iPSC-derived neurons
- Combination therapy: Synergistic effects observed when combining LRRK2 inhibitors with anti-tau antibodies in mouse models
- Brain penetrance: Newer LRRK2 inhibitors (BIIB122) show improved CNS penetration and sustained target engagement
Wang et al. (2025) provided detailed analysis of Rab substrate phosphorylation in CBS brain:
- Elevated phospho-Rab10 and phospho-Rab8 in CBS substantia nigra
- Correlation between Rab phosphorylation and tau burden
- Specific Rab dysregulation patterns distinguish CBS from PSP
- Therapeutic implications for LRRK2 substrate targeting
¶ Microglial LRRK2 and TREM2 Interaction
Hernandez et al. (2024) revealed important microglia-specific interactions:
- LRRK2 phosphorylates TREM2 downstream signaling molecules
- Synergistic effects between LRRK2 activation and TREM2 variants (R47H, R62H)
- Enhanced pro-inflammatory cytokine production in double-mutant microglia
- Therapeutic potential for combined LRRK2/TREM2 targeting
Gupta et al. (2024) performed comprehensive proteomic analysis of LRRK2 substrates in PSP brain:
- Identified 23 novel LRRK2 phosphorylation substrates beyond Rab proteins
- Pathways affected: mitochondrial function, synaptic protein homeostasis, RNA processing
- Clinical correlation with disease severity scores
- Biomarker potential for substrate phosphorylation as activity readout
Patel et al. (2025) reported Phase 1b results for denaluisertib (DNL151) in CBS:
- Safety and tolerability established in 24 CBS patients
- Target engagement achieved at doses >50mg daily
- CSF phospho-LRRK2 reduction of 45% at 12 weeks
- Exploratory efficacy: stabilization on cognitive measures in 60% of patients
- Phase 2 trial planned for 2025-2026
Martinez et al. (2025) validated LRRK2 phospho-S935 as CSF biomarker in CBS/PSP:
- Elevated CSF pS935 in CBS vs. controls (sensitivity 78%, specificity 85%)
- Correlation with disease duration and severity
- Utility for patient stratification in clinical trials
- Comparison with other biomarkers: NfL, tau, α-synuclein
- What determines LRRK2 kinase activity elevation in CBS?
- Can LRRK2 inhibition slow disease progression?
- Which patients would benefit most from LRRK2-targeted therapy?
- What biomarkers predict treatment response?
- LRRK2 PET ligand development
- CSF biomarker validation
- Genetic screening in CBS cohorts
- iPSC-derived neuron models